{"id":"https://openalex.org/W3021740372","doi":null,"title":"Monoclonal Antibody Therapy for Neuromyelitis Optica: A Systematic Review and Meta-Analysis","display_name":"Monoclonal Antibody Therapy for Neuromyelitis Optica: A Systematic Review and Meta-Analysis","publication_year":2019,"publication_date":"2019-01-01","ids":{"openalex":"https://openalex.org/W3021740372","mag":"3021740372"},"language":"en","primary_location":{"id":"mag:3021740372","doi":null,"is_oa":false,"landing_page_url":"https://www.hilarispublisher.com/open-access/monoclonal-antibody-therapy-for-neuromyelitis-optica-a-systematic-review-and-metaanalysis.pdf","pdf_url":null,"source":{"id":"https://openalex.org/S4306520754","display_name":"Neurological Disorders","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Neurological Disorders","raw_type":null},"volume":null,"type":"review","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5012993877","display_name":"Jonathan Thomas Caranfa","orcid":"https://orcid.org/0000-0002-3476-3431","observed_orcids":["https://orcid.org/0000-0002-3476-3431"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Caranfa Jt","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032615520","display_name":"Christine G. Kohn","orcid":"https://orcid.org/0000-0003-4372-2700","observed_orcids":["https://orcid.org/0000-0003-4372-2700"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kohn Cg","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030712428","display_name":"Baker Wl","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Baker Wl","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5103461437","display_name":"David M. Waitzman","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Waitzman Dm","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"7","issue":"3","first_page":"1","last_page":"6"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11735","display_name":"Peripheral Neuropathies and Disorders","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11827","display_name":"Polyomavirus and related diseases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/neuromyelitis-optica","display_name":"neuromyelitis optica","score":0.9850000143051147},{"id":"https://openalex.org/keywords/nmo-spectrum-disorders","display_name":"NMO spectrum disorders","score":0.8859999775886536},{"id":"https://openalex.org/keywords/monoclonal-antibody-therapy","display_name":"monoclonal antibody therapy","score":0.9039999842643738},{"id":"https://openalex.org/keywords/rituximab","display_name":"rituximab","score":1.0},{"id":"https://openalex.org/keywords/eculizumab","display_name":"eculizumab","score":1.0},{"id":"https://openalex.org/keywords/tocilizumab","display_name":"tocilizumab","score":1.0},{"id":"https://openalex.org/keywords/annualized-relapse-rate","display_name":"annualized relapse rate","score":0.8899999856948853},{"id":"https://openalex.org/keywords/expanded-disability-status-scale","display_name":"Expanded Disability Status Scale","score":0.972000002861023},{"id":"https://openalex.org/keywords/neurological-deficit","display_name":"neurological deficit","score":0.7630000114440918},{"id":"https://openalex.org/keywords/autoimmune-disease","display_name":"autoimmune disease","score":0.4410000145435333}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9119032621383667},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.9058268666267395},{"id":"https://openalex.org/C2781137167","wikidata":"https://www.wikidata.org/wiki/Q611458","display_name":"Neuromyelitis optica","level":3,"score":0.8948497772216797},{"id":"https://openalex.org/C2777178219","wikidata":"https://www.wikidata.org/wiki/Q425154","display_name":"Tocilizumab","level":3,"score":0.8804369568824768},{"id":"https://openalex.org/C2777991916","wikidata":"https://www.wikidata.org/wiki/Q421617","display_name":"Eculizumab","level":4,"score":0.7504795789718628},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5480589270591736},{"id":"https://openalex.org/C2777843201","wikidata":"https://www.wikidata.org/wiki/Q17163357","display_name":"Monoclonal antibody therapy","level":4,"score":0.5313302278518677},{"id":"https://openalex.org/C2777154362","wikidata":"https://www.wikidata.org/wiki/Q7575316","display_name":"Spectrum disorder","level":2,"score":0.44672852754592896},{"id":"https://openalex.org/C2780892749","wikidata":"https://www.wikidata.org/wiki/Q929518","display_name":"Expanded Disability Status Scale","level":3,"score":0.44076237082481384},{"id":"https://openalex.org/C95190672","wikidata":"https://www.wikidata.org/wiki/Q815382","display_name":"Meta-analysis","level":2,"score":0.43758878111839294},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.4278392791748047},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.3778928518295288},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.2803906202316284},{"id":"https://openalex.org/C2780640218","wikidata":"https://www.wikidata.org/wiki/Q8277","display_name":"Multiple sclerosis","level":2,"score":0.269074946641922},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.2330053150653839},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.23021665215492249},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.15639320015907288},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.05321231484413147},{"id":"https://openalex.org/C111684460","wikidata":"https://www.wikidata.org/wiki/Q334848","display_name":"Complement system","level":3,"score":0.0},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:3021740372","doi":null,"is_oa":false,"landing_page_url":"https://www.hilarispublisher.com/open-access/monoclonal-antibody-therapy-for-neuromyelitis-optica-a-systematic-review-and-metaanalysis.pdf","pdf_url":null,"source":{"id":"https://openalex.org/S4306520754","display_name":"Neurological Disorders","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Neurological Disorders","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/systematic-review","display_name":"Systematic Review"},{"id":"https://openalex.org/study-designs/meta-analysis","display_name":"Meta-Analysis"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":19,"referenced_works":["https://openalex.org/W1991019975","https://openalex.org/W2007556864","https://openalex.org/W2089363506","https://openalex.org/W2095812817","https://openalex.org/W2100224535","https://openalex.org/W2107941546","https://openalex.org/W2111827868","https://openalex.org/W2114414511","https://openalex.org/W2125435699","https://openalex.org/W2128640268","https://openalex.org/W2130342500","https://openalex.org/W2156098321","https://openalex.org/W2157823046","https://openalex.org/W2524675862","https://openalex.org/W2551229111","https://openalex.org/W2568116806","https://openalex.org/W2570909152","https://openalex.org/W2791305328","https://openalex.org/W2899093568"],"related_works":["https://openalex.org/W3024107893","https://openalex.org/W3113683639","https://openalex.org/W4280509510","https://openalex.org/W7129682476","https://openalex.org/W4362561528","https://openalex.org/W4220852900","https://openalex.org/W2525224202","https://openalex.org/W3185357728","https://openalex.org/W4323531674","https://openalex.org/W7126269677"],"abstract_inverted_index":{"Background:":[0],"Neuromyelitis":[1],"optica":[2],"(NMO)":[3],"and":[4,53,59,64,80,101,107,115,130,150,172,181],"NMO":[5],"spectrum":[6],"disorder":[7,13],"(NMOSD)":[8],"is":[9],"a":[10,50,136,151],"rare":[11],"autoimmune":[12],"that":[14],"often":[15],"leaves":[16],"patients":[17,100,123],"severely":[18],"disabled,":[19],"despite":[20],"aggressive":[21],"treatment":[22],"with":[23,166],"traditional":[24],"immunosuppressive":[25],"medication.":[26],"While":[27],"monoclonal":[28,117,167],"antibody":[29],"therapy":[30,133],"has":[31],"shown":[32],"efficacy":[33,58],"in":[34,66,98,126,135,141,156,185],"treating":[35],"NMO/NMOSD,":[36],"no":[37],"large":[38],"randomized":[39],"control":[40],"trials":[41],"exist.":[42],"In":[43],"lieu":[44],"of":[45,61,76,143,158,178],"such":[46],"trials,":[47],"we":[48],"performed":[49],"systematic":[51,128],"review":[52,129],"meta-analysis":[54],"to":[55,148,163],"assess":[56],"the":[57,72,127,176],"safety":[60],"rituximab,":[62,94,170],"eculizumab":[63,95,171],"tocilizumab":[65,97],"NMO/NMOSD":[67,99,186],"patients.\r\nMethods:":[68],"We":[69],"searched":[70],"MEDLINE,":[71],"Cochrane":[73],"Central":[74],"Register":[75],"Controlled":[77],"Trials":[78],"(CENTRAL)":[79],"Embase":[81],"from":[82],"January":[83],"1,":[84],"2006":[85],"through":[86],"December":[87],"31,":[88],"2018":[89],"for":[90],"prospective":[91],"studies":[92,120],"using":[93],"or":[96],"reporting":[102],"annual":[103],"relapse":[104],"rate":[105],"(ARR)":[106],"Expanded":[108],"Disability":[109],"Status":[110],"Scale":[111],"(EDSS)":[112],"score":[113],"before":[114],"after":[116],"therapy.\r\nResults:":[118],"Sixteen":[119],"involving":[121],"324":[122],"were":[124],"included":[125],"meta-analysis.":[131],"Monoclonal":[132],"resulted":[134],"statistically":[137,152],"significant":[138,153],"mean":[139,154],"reduction":[140,155],"ARR":[142],"1.77":[144],"(95%":[145,160],"CI,":[146,161],"1.37":[147],"2.17)":[149],"EDSS":[157],"1.14":[159],"0.87":[162],"1.41).\r\nConclusion:":[164],"Treatment":[165],"antibodies,":[168],"specifically":[169],"tocilizumab,":[173],"significantly":[174],"reduced":[175],"frequency":[177],"disease":[179],"relapses":[180],"improved":[182],"neurological":[183],"disability":[184],"patients.":[187]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2020-05-13T00:00:00"}